Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 21, 2009

Roche and Sigma-Aldrich to Co-Market Complementary Platforms for Epigenetic Research

  • Roche NimbleGen is aligning its ChIP-chip high-density microarrays with Sigma-Aldrich’s GenomePlex. The companies will co-market these complementary technologies.

    To facilitate the ChIP-chip workflow, Roche NimbleGen and Sigma-Aldrich will publish protocols for such research and provide technical support to investigators integrating the two technologies.

    The technologies from Sigma-Aldrich and Roche NimbleGen reportedly facilitate effective ChIP-chip research by addressing two critical bottlenecks in the workflow: efficient amplification of targeted sections of DNA and high-resolution microarray detection. GenomePlex can amplify targeted DNA fragments that are smaller than 200 bp in an efficient and unbiased manner, according to Sigma-Aldrich. The amplified genome can then be analyzed on Roche NimbleGen’s high-density (up to 2.1 million probes per array), long oligonucleotide,ChIP-chip arrays.

    Together, the platforms enable researchers to study the entire genome for epigenetic interactions between DNA and DNA-binding proteins to determine regions of the genome that are transcriptionally active or repressed and the mechanisms that regulate these processes.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »